My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 804 / https://doi.org/10.3332/ecancer.2018.804

Research

Men seeking counselling in a Breast Cancer Risk Evaluation Clinic

Background: Hereditary breast and ovary cancer syndrome affects both genders but little is known about the uptake of genetic services by men. The objective of this study is to characterise the male population counselled through a multidisciplinary breast/ovarian program.

Methods: Descriptive analysis of male patients counselled from January 2000 to December 2015. Data in this analysis include new cancer diagnoses during prospective follow up.

Results: From 4,320 families registered, 362 male patients were identified: 236 (65.2%) from hereditary cancer families (HCF) and 126 (34.8%) from non-HCF. In HCF, 121 patients (51.3%) were mutation carriers (MC): BRCA2 – 102 (84.3%), BRCA1 – 16 (13.2%), CHEK2 – 1 (0.8%) and TP53 – 2 (1.7%). Non-HCF included 126 patients: 85 (67.5%) belonged to families without pathogenic mutations or with variants of unknown clinical significance; 22 (17.5%) refused testing after counselling and 19 (15.0%) did not meet criteria for testing. Both HCF and non-HCF included patients with previous cancer diagnoses: HCF- Breast Cancer (BC) - 18; prostate cancer (PC) - 13; melanoma - 1; others - 7) and non-HCF (BC - 77; PC - 20; gastric cancer (GC) - 1; melanoma - 8; bladder cancer - 1; others - 22). From the 121 MC identified (including the TP53 and CHEK2 carriers), 97 patients (80.2%) adhered to prospective surveillance. With a median follow-up of 36.9 months, 17 cancers were diagnosed in 14 patients, PC being the most frequently diagnosed neoplasia (5 cases). Eleven patients (78.6%) are alive and three patients died of advanced cancer (2 with GC, 1 with disseminated adenocarcinoma).

Conclusion: We observed a high adherence to counselling, genetic testing and active surveillance by men belonging to hereditary BC families. Male carriers of pathogenic DNA variants are at risk for several cancers and should be included in prospective follow-up studies.

Keywords: hereditary cancer, germline mutations, genetic counselling, genetic testing, breast cancer, prostate cancer, surveillance program

Loading Article Metrics ... Please wait

Related articles

Research: MGMT promoter methylation in Peruvian patients with glioblastoma

Abstract | Full Article | PDF Published: 14 Feb 2018 / https://doi.org/10.3332/ecancer.2018.812

Case Report: Palliative hysterectomy for vaginal bleeding from breast cancer metastatic to the uterus

Abstract | Full Article | PDF Published: 14 Feb 2018 / https://doi.org/10.3332/ecancer.2018.811

Case Report: Secondary breast cancer after Hodgkin lymphoma: a case report and literature review

Abstract | Full Article | PDF Published: 14 Feb 2018 / https://doi.org/10.3332/ecancer.2018.810

Short Communication: InforMD: a new initiative to raise public awareness about breast density

Abstract | Full Article | PDF Published: 06 Feb 2018 / https://doi.org/10.3332/ecancer.2018.807

Research: Knowledge and attitude of women regarding breast cancer screening tests in Eastern Iran

Abstract | Full Article | PDF Published: 05 Feb 2018 / https://doi.org/10.3332/ecancer.2018.806



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence